Xencor Presents Final Results from Phase 2 Study of XmAb®5871 in IgG4-Related Disease (IgG4-RD) at the American College of Rheumatology 2017 Annual Meeting Read more about Xencor Presents Final Results from Phase 2 Study of XmAb®5871 in IgG4-Related Disease (IgG4-RD) at the American College of Rheumatology 2017 Annual Meeting
Xencor to Present at Upcoming Investor Conferences Read more about Xencor to Present at Upcoming Investor Conferences
Xencor to Host Third Quarter 2017 Financial Results Webcast and Conference Call on November 7, 2017 Read more about Xencor to Host Third Quarter 2017 Financial Results Webcast and Conference Call on November 7, 2017
Xencor to Present Final Results from Phase 2 Study of XmAb®5871 in IgG4-Related Disease at American College of Rheumatology (ACR) 2017 Annual Meeting Read more about Xencor to Present Final Results from Phase 2 Study of XmAb®5871 in IgG4-Related Disease at American College of Rheumatology (ACR) 2017 Annual Meeting
Xencor to Present at Upcoming Investor Conferences Read more about Xencor to Present at Upcoming Investor Conferences
Xencor Reports Second Quarter 2017 Financial Results Read more about Xencor Reports Second Quarter 2017 Financial Results
Xencor to Present at Upcoming Investor Conferences Read more about Xencor to Present at Upcoming Investor Conferences
Xencor to Host Second Quarter 2017 Financial Results Webcast and Conference Call on August 7, 2017 Read more about Xencor to Host Second Quarter 2017 Financial Results Webcast and Conference Call on August 7, 2017
Xencor Presents Interim Data from an Ongoing, Open-label, Phase 2 Study of XmAb®5871 in IgG4-Related Disease at EULAR 2017 Read more about Xencor Presents Interim Data from an Ongoing, Open-label, Phase 2 Study of XmAb®5871 in IgG4-Related Disease at EULAR 2017
Xencor Appoints Raphael Clynes, M.D., Ph.D., as Vice President of Translational Biology Read more about Xencor Appoints Raphael Clynes, M.D., Ph.D., as Vice President of Translational Biology
